<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Symptom Advice .com &#187; suitability</title>
	<atom:link href="http://symptomadvice.com/tag/suitability/feed/" rel="self" type="application/rss+xml" />
	<link>http://symptomadvice.com</link>
	<description></description>
	<lastBuildDate>Tue, 29 May 2012 22:17:13 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.0.1</generator>
		<item>
		<title>Hemispherx Biopharma shares rise on FDA extension of new drug application</title>
		<link>http://symptomadvice.com/hemispherx-biopharma-shares-rise-on-fda-extension-of-new-drug-application/</link>
		<comments>http://symptomadvice.com/hemispherx-biopharma-shares-rise-on-fda-extension-of-new-drug-application/#comments</comments>
		<pubDate>Fri, 13 Jan 2012 07:34:13 +0000</pubDate>
		<dc:creator>Symptom Advice</dc:creator>
				<category><![CDATA[fatigue symptoms]]></category>
		<category><![CDATA[disclosure]]></category>
		<category><![CDATA[investment advice]]></category>
		<category><![CDATA[investment strategy]]></category>
		<category><![CDATA[regard]]></category>
		<category><![CDATA[suitability]]></category>

		<guid isPermaLink="false">http://symptomadvice.com/hemispherx-biopharma-shares-rise-on-fda-extension-of-new-drug-application/</guid>
		<description><![CDATA[No investment advice The Company &#105;&#115; a publisher and &#105;&#115; not registered &#119;&#105;&#116;&#104; &#111;&#114; authorised by the Financial Services Authority (FSA). &#121;&#111;&#117; understand and agree that &#110;&#111; content published on the Site constitutes a recommendation that &#097;&#110;&#121; particular security, portfolio &#111;&#102; securities, transaction, &#111;&#114; investment strategy &#105;&#115; suitable &#111;&#114; advisable for &#097;&#110;&#121; specific person. &#121;&#111;&#117; [...]]]></description>
			<content:encoded><![CDATA[<p></p><p><img src="" style="float:left;clear:both;margin:0 15px 15px 0" />No investment advice
<p>The Company &#105;&#115; a publisher and &#105;&#115; not registered &#119;&#105;&#116;&#104; &#111;&#114; authorised by the Financial Services Authority (FSA). &#121;&#111;&#117; understand and agree that &#110;&#111; content published on the Site constitutes a recommendation that &#097;&#110;&#121; particular security, portfolio &#111;&#102; securities, transaction, &#111;&#114; investment strategy &#105;&#115; suitable &#111;&#114; advisable for &#097;&#110;&#121; specific person. &#121;&#111;&#117; &#102;&#117;&#114;&#116;&#104;&#101;&#114; understand that &#110;&#111;&#110;&#101; &#111;&#102; the information providers &#111;&#114; their affiliates &#119;&#105;&#108;&#108; advise &#121;&#111;&#117; personally &#099;&#111;&#110;&#099;&#101;&#114;&#110;&#105;&#110;&#103; the nature, potential, advisability, value &#111;&#114; suitability &#111;&#102; &#097;&#110;&#121; particular security, portfolio &#111;&#102; securities, transaction, investment strategy, &#111;&#114; other matter.</p>
<p>You understand that the Site &#109;&#097;&#121; &#099;&#111;&#110;&#116;&#097;&#105;&#110; opinions &#102;&#114;&#111;&#109; time &#116;&#111; time &#119;&#105;&#116;&#104; regard &#116;&#111; securities mentioned in other products, including company related products, and that those opinions &#109;&#097;&#121; be different &#102;&#114;&#111;&#109; those obtained by using another product related &#116;&#111; the Company. &#121;&#111;&#117; understand and agree that contributors &#109;&#097;&#121; write &#097;&#098;&#111;&#117;&#116; securities in &#119;&#104;&#105;&#099;&#104; &#116;&#104;&#101;&#121; &#111;&#114; their firms have a position, and that &#116;&#104;&#101;&#121; &#109;&#097;&#121; trade such securities for their &#111;&#119;&#110; account. In cases where the position &#105;&#115; held at the time &#111;&#102; publication and such position &#105;&#115; &#107;&#110;&#111;&#119;&#110; &#116;&#111; the Company, appropriate disclosure &#105;&#115; made. &#104;&#111;&#119;&#101;&#118;&#101;&#114;, &#121;&#111;&#117; understand and agree that at the time &#111;&#102; &#097;&#110;&#121; transaction that &#121;&#111;&#117; make, &#111;&#110;&#101; &#111;&#114; more contributors &#109;&#097;&#121; have a position in the securities written &#097;&#098;&#111;&#117;&#116;. &#121;&#111;&#117; understand that price and other data &#105;&#115; supplied by sources believed &#116;&#111; be reliable, that the calculations &#104;&#101;&#114;&#101;&#105;&#110; are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers &#111;&#114; &#097;&#110;&#121; other person &#111;&#114; entity, and &#109;&#097;&#121; not be complete &#111;&#114; accurate.</p>
<p>From time &#116;&#111; time, reference &#109;&#097;&#121; be made in &#111;&#117;&#114; marketing materials &#116;&#111; prior articles and opinions we have published. These references &#109;&#097;&#121; be selective, &#109;&#097;&#121; reference &#111;&#110;&#108;&#121; a portion &#111;&#102; an article &#111;&#114; recommendation, and are likely not &#116;&#111; be current. As markets change continuously, previously published information and data &#109;&#097;&#121; not be current and &#115;&#104;&#111;&#117;&#108;&#100; not be relied upon.</p></p>
]]></content:encoded>
			<wfw:commentRss>http://symptomadvice.com/hemispherx-biopharma-shares-rise-on-fda-extension-of-new-drug-application/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
